Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology August 29, 2022 August 29, 2022
An impact company committed to improving the health of patients worldwide, MedinCell publishes its 2021-2022 ESG annual report August 17, 2022 August 17, 2022
MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report July 29, 2022 July 29, 2022
Long-acting injectable formulation technologies: Challenges and opportunities for the delivery of fragile molecules July 28, 2022 July 28, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000 July 27, 2022 July 27, 2022
MedinCell announces its full year financial results April 2021 – March 2022 June 14, 2022 June 14, 2022
Videoconference and release of fiscal 2021-2022 financial results on June 14, 2022 June 7, 2022 June 7, 2022
MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer May 9, 2022 May 9, 2022
MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM May 3, 2022 May 3, 2022
